ARCHIVES

In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.

This article is from The Cancer Letter archive.

Vol. 30 No. 21 | May 21, 2004

Download PDF Visit The Full Archive

Related Articles

NCCN Updates Breast Cancer Guidelines for Patients

October 31, 2003

Revive Comprehensive Program, But Don’t Tie It to Grant Review, Center Executive Agrees

July 29, 1988

Early-Stage HER2+ Breast Cancer Patients Are At Significant Risk Of Recurrence

December 26, 2008

FDA’s New Guideline Proposal Meets More NCI Objections

March 19, 1976

In Brief: NCI Gets $867 Million From Conferees; Grants To Be Funded At 41-42% Including Some Holdovers

July 29, 1977

Funding opportunities listed.

November 12, 2004